Gastric biomarkers: a global review

被引：79
作者：
Baniak, Nick [1 ]
Senger, Jenna-Lynn [2 ]
Ahmed, Shahid [3 ]
Kanthan, S. C. [4 ]
Kanthan, Rani [4 ]
机构：
[1] Univ Saskatchewan, Dept Pathol & Lab Med, 103 Hosp Dr, Saskatoon, SK S7N 0W8, Canada
[2] Univ Alberta, Dept Surg, 116 St & 85 Ave, Edmonton, AB T6G 2B7, Canada
[3] Univ Saskatchewan, Div Med Oncol, 103 Hosp Dr, Saskatoon, SK S7N 0W8, Canada
[4] Univ Saskatchewan, Dept Gen Surg, 103 Hosp Dr, Saskatoon, SK S7N 0W8, Canada
来源：
WORLD JOURNAL OF SURGICAL ONCOLOGY | 2016年 / 14卷
关键词：
Gastric cancer; Biomarkers; Therapy; HER2 GENE AMPLIFICATION; IN-SITU HYBRIDIZATION; E-CADHERIN GENE; LONG NONCODING RNAS; MICROSATELLITE INSTABILITY; CLINICOPATHOLOGICAL FEATURES; GASTROESOPHAGEAL JUNCTION; PROTEIN EXPRESSION; PHASE-II; MATRIX METALLOPROTEINASES;
D O I：
10.1186/s12957-016-0969-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Background: Gastric cancer is an aggressive disease with a poor 5-year survival and large global burden of disease. The disease is biologically and genetically heterogeneous with a poorly understood carcinogenesis at the molecular level. Despite the many prognostic, predictive, and therapeutic biomarkers investigated to date, gastric cancer continues to be detected at an advanced stage with resultant poor clinical outcomes. Main body: This is a global review of gastric biomarkers with an emphasis on HER2, E-cadherin, fibroblast growth factor receptor, mammalian target of rapamycin, and hepatocyte growth factor receptor as well as sections on microRNAs, long noncoding RNAs, matrix metalloproteinases, PD-L1, TP53, and microsatellite instability. Conclusion: A deeper understanding of the pathogenesis and biological features of gastric cancer, including the identification and characterization of diagnostic, prognostic, predictive, and therapeutic biomarkers, hopefully will provide improved clinical outcomes.
引用
收藏
页数：14
相关论文
共 179 条
  • [51] Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas
    Gallardo, A.
    Lerma, E.
    Escuin, D.
    Tibau, A.
    Munoz, J.
    Ojeda, B.
    Barnadas, A.
    Adrover, E.
    Sanchez-Tejada, L.
    Giner, D.
    Ortiz-Martinez, F.
    Peiro, G.
    [J]. BRITISH JOURNAL OF CANCER, 2012, 106 (08) : 1367 - 1373
  • [52] E-Cadherin expression in Sporadic Gastric cancer from Mexico:: Exon 8 and 9 deletions are infrequent events associated with poor survival
    Gamboa-Dominguez, A
    Dominguez-Fonseca, C
    Chavarri-Guerra, Y
    Vargas, R
    Reyes-Gutierrez, E
    Green, D
    Quintanilla-Martinez, L
    Luber, B
    Busch, R
    Becker, KF
    Becker, I
    Höfler, H
    Fend, F
    [J]. HUMAN PATHOLOGY, 2005, 36 (01) : 29 - 35
  • [53] Serum MicroRNAs Are Promising Novel Biomarkers
    Gilad, Shlomit
    Meiri, Eti
    Yogev, Yariv
    Benjamin, Sima
    Lebanony, Danit
    Yerushalmi, Noga
    Benjamin, Hila
    Kushnir, Michal
    Cholakh, Hila
    Melamed, Nir
    Bentwich, Zvi
    Hod, Moshe
    Goren, Yaron
    Chajut, Ayelet
    [J]. PLOS ONE, 2008, 3 (09):
  • [54] A critical review of HER2-positive gastric cancer evaluation and treatment: From trastuzumab, and beyond
    Gomez-Martin, Carlos
    Lopez-Rios, Fernando
    Aparicio, Jorge
    Barriuso, Jorge
    Garcia-Carbonero, Rocio
    Pazo, Roberto
    Rivera, Fernando
    Salgado, Mercedes
    Salud, Antonieta
    Vazquez-Sequeiros, Enrique
    Lordick, Florian
    [J]. CANCER LETTERS, 2014, 351 (01) : 30 - 40
  • [55] HER2/neu testing for anti-HER2-based therapies in patients with unresectable and/or metastatic gastric cancer
    Gomez-Martin, Carlos
    Garralda, Elena
    Jose Echarri, M.
    Ballesteros, Anabel
    Arcediano, Alberto
    Luis Rodriguez-Peralto, Jose
    Hidalgo, Manuel
    Lopez-Rios, Fernando
    [J]. JOURNAL OF CLINICAL PATHOLOGY, 2012, 65 (08) : 751 - 757
  • [56] Evaluating the Consistency of Differential Expression of MicroRNA Detected in Human Cancers
    Gong, Xue
    Wu, Ruihong
    Wang, Hongwei
    Guo, Xinwu
    Wang, Dong
    Gu, Yunyan
    Zhang, Yuannv
    Zhao, Wenyuan
    Cheng, Lixin
    Wang, Chenguang
    Guo, Zheng
    [J]. MOLECULAR CANCER THERAPEUTICS, 2011, 10 (05) : 752 - 760
  • [57] Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial
    Gordon, M. A.
    Gundacker, H. M.
    Benedetti, J.
    Macdonald, J. S.
    Baranda, J. C.
    Levin, W. J.
    Blanke, C. D.
    Elatre, W.
    Weng, P.
    Zhou, J. Y.
    Lenz, H. J.
    Press, M. F.
    [J]. ANNALS OF ONCOLOGY, 2013, 24 (07) : 1754 - 1761
  • [58] HER2 expression in gastric cancer: Rare, heterogeneous and of no prognostic value - conclusions from 924 cases of two independent series
    Grabsch, Heike
    Sivakumar, Shivan
    Gray, Sally
    Gabbert, Helmut E.
    Mueller, Wolfram
    [J]. CELLULAR ONCOLOGY, 2010, 32 (1-2) : 57 - 65
  • [59] Methylation of the CDH1 promoter as the second genetic hit in hereditary diffuse gastric cancer
    Grady, WM
    Willis, J
    Guilford, PJ
    Dunbier, AK
    Toro, TT
    Lynch, H
    Wiesner, G
    Ferguson, K
    Eng, C
    Park, JG
    Kim, SJ
    Markowitz, S
    [J]. NATURE GENETICS, 2000, 26 (01) : 16 - 17
  • [60] HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target
    Gravalos, C.
    Jimeno, A.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 (09) : 1523 - 1529
12345678910